The 17th Annual Meeting of the Japanese Society of Safety Pharmacology is scheduled to take place at Sonic City in Omiya, Saitama Prefecture, on February 26 (Thursday) and 27 (Friday), 2026.
The theme of this year’s meeting is “Next-Generation Safety Pharmacology: Succession and Innovation.” In recent years, with the increasing development of various new modalities, safety pharmacology endpoints have been incorporated into general toxicity studies, and new evaluation methods utilizing NAMs (New Approach Methodologies) are being explored. Furthermore, the issuance of Q&As and Best Practices for the ICH E14/S7B guidelines has led to new initiatives in the field of regulatory science.
This annual meeting aims to provide a platform for discussing not only conventional evaluation methods but also the development of new safety pharmacology assessment systems that incorporate innovative technologies. We are planning an international invited lecture directly related to the Q&As, and in the symposium sessions, experts active in the fields of cardiovascular and central nervous systems will deliver talks offering insights aligned with the meeting’s theme. In the educational lecture, a presentation by regulatory authorities will be followed by a workshop to deepen participants’ understanding. Additionally, pharmaceutical companies will present case studies on strategies for addressing safety concerns, and—as in previous years—we are planning interactive workshops to encourage active participation. For the poster session, we are preparing to accept numerous research presentations, as in previous years. We look forward to your submissions and encourage you to apply for the Excellent Research Presentation Award.
This 17th Annual Meeting will be held in the Kanto region, and the organizing committee is making every effort to ensure it will be a fruitful and rewarding events for all participants. Although it is a busy at the end of the fiscal year, we sincerely hope that many of you will be able to attend in person.
The 17th Annual Meeting President:
Takafumi Shirakawa
(Astellas Pharma Inc.)
